ROS Therapeutics ApS: Financial statements 2025
CVR: 39507501
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ROS Therapeutics ApS (CVR 39507501) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408. The company had 1 employee in the financial year.
- Gross Profit
- DKK -543,530
- Profit/Loss
- DKK -1,212,924
- Equity
- DKK -7,954,408
- Total Assets
- DKK 602,418
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -544 t. | -1.2 mio. | -8 mio. | 1 |
| 2024 | - | -584 t. | -1.3 mio. | -6.6 mio. | 1 |
| 2023 | - | -678 t. | -1.2 mio. | -5.3 mio. | 1 |
| 2022 | - | -3.1 mio. | -3.4 mio. | -4.1 mio. | 1 |
| 2021 | - | -4.8 mio. | -4.4 mio. | -758 t. | 1 |
Official annual report
How creditworthy is ROS Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of August 15, 2025, BDO Statsautoriseret Revisionspartnerselskab has been appointed auditor of ROS Therapeutics ApS.
As of August 15, 2025, A/S PSE 17 NR. 1056 has stepped down as auditor of ROS Therapeutics ApS.
ROS Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -583,751, and the net result was DKK -1,314,915.
About ROS Therapeutics ApS
ROS Therapeutics ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company is in liquidation. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.